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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:
To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for screening for tuberculosis in adults irrespective of signs or symptoms of
pulmonary tuberculosis in the general population (i.e. low-risk population).
To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for screening of pulmonary tuberculosis in adults in the following high-risk
groups.
• People living with HIV.
• Household contacts of people with tuberculosis.
• Patients residing in high-tuberculosis-burden settings attending primary health facilities.
• Homeless people.
• Miners.
• People with diabetes mellitus.
• People who abuse alcohol.
• Smokers.
• People residing in prisons.
• Healthcare workers.
To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for the detection of rifampicin resistance in the general population and in the
high-risk groups and settings described above.
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Secondary objectives
To compare the accuracy of Xpert MTB/RIF and Xpert Ultra in the above high-risk groups and settings.
To investigate potential sources of heterogeneity in accuracy estimates, including the percentage of participants with tuberculosis
symptoms, tuberculosis burden, tuberculosis/HIV burden, and MDR-TB burden.
Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of
pulmonary tuberculosis (Protocol)
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B A C K G R O U N D
Tuberculosis is the world’s leading cause of infectious disease-
related death and is one of the top 10 causes of death worldwide
(WHO Global TB Report 2019). In 2018, an estimated 10 million
people developed tuberculosis disease, a 2% decline from 2017
(MacNeil 2020; WHO Global TB Report 2019).
Among all tuberculosis cases, about 9% were in people living
with HIV (WHO Global TB Report 2019). The risk of developing
tuberculosis is much higher in people living with HIV, estimated
to be 20 to 37 times higher in HIV-positive individuals than in
HIV-negative individuals (Getahun 2010). Signs and symptoms
of tuberculosis in people living with HIV vary, which makes
it challenging to determine when to consider a diagnosis of
tuberculosis - tuberculosis is the leading cause of hospitalization
and death in people with HIV worldwide (Ford 2016). In addition,
there were around 500,000 new cases of rifampicin-resistant
tuberculosis, of which 78% had multidrug-resistant tuberculosis
(tuberculosis that is resistant to both rifampicin and isoniazid, the
two most essential anti-tuberculosis drugs) (WHO Global TB Report
2019). When tuberculosis is detected early and is eJectively treated,
the disease is largely curable. Ending the tuberculosis epidemic
by 2030 is among the health-related targets described in United
Nations Sustainable Development Goal 3 (WHO END TB 2015).
The United Nations Sustainable Development Goals represent a
collective plan to end poverty, decrease inequality, and protect the
planet from degradation by 2030 (UN Sustainable Development
Goals 2030).
The World Health Organization (WHO) recommends the use of
specific molecular tests, including Xpert MTB/RIF or Xpert Ultra,
the newest version of the assay, as the initial diagnostic tests for
the detection of tuberculosis and rifampicin resistance in people
with signs and symptoms of tuberculosis (WHO Xpert MTB/RIF
2013; WHO Xpert Ultra 2017; WHO Rapid Communication 2020a).
However, the WHO estimates that nearly one-third of all active
tuberculosis cases go undiagnosed and unreported (WHO Global
TB Report 2019). In an eJort to close this diagnostic gap, the
WHO is seeking evidence to recommend case-finding approaches
and strategies to improve tuberculosis case detection of the
'missing millions'. In particular, the WHO is interested in case-
finding approaches in high-risk populations and settings, such as
people living with HIV, people with diabetes mellitus, and people
residing in prisons. Stated another way, the WHO is interested in the
best ways to find the so-called ‘missing millions’.
Tuberculosis screening is a term that has been used diJerently
in the literature depending on the context. We use tuberculosis
screening as defined by the WHO: the "systematic identification of
people with suspected active TB [tuberculosis], in a predetermined
target group, using tests, examinations or other procedures that
can be applied rapidly." Further, we define intensified case-finding
as tuberculosis screening activities set in health facilities, and
active case-finding as tuberculosis screening activities set in
the community, including household-based or residence-based
screening activities (WHO Tuberculosis screening 2013). The End-
TB strategy emphasizes early diagnosis of tuberculosis, including
universal drug susceptibility testing, and systematic screening of
contacts and high-risk groups (WHO Global TB Report 2019).
Current screening approaches for active tuberculosis typically
recommend initial screening for four cardinal signs and symptoms
of tuberculosis: cough, fever, weight loss, and night sweats. People
with a positive symptom screen then may go on to receive
additional screening with a chest X-ray and diagnostic testing using
sputum Xpert MTB/RIF or Xpert Ultra as recommended. Concerning
people living with HIV, a recent systematic review found that
the four-symptom screen had lower sensitivity and specificity for
active tuberculosis in HIV-positive people on antiretroviral therapy
(ART) than in HIV-positive people not taking ART (Hamada 2018).
Compared to Xpert MTB/RIF, Xpert Ultra has shown increased
sensitivity for tuberculosis in HIV-positive people (Dorman 2018).
WHO Tuberculosis Standard 8 states, "For persons living with
HIV, the Xpert MTB/RIF Ultra assay should be used as an initial
diagnostic test" (WHO Compendium of WHO guidelines 2018).
Several Cochrane Reviews have been published or are in process
to assess the diagnostic accuracy of Xpert MTB/RIF and Xpert
Ultra for diJerent target conditions and in various populations. Of
relevance to the current review, a recent Cochrane Review found
Xpert MTB/RIF and Xpert Ultra to be highly sensitive and specific
for pulmonary tuberculosis and rifampicin resistance in adults with
signs and symptoms of tuberculosis (Horne 2019). The current
review will determine the accuracy of Xpert MTB/RIF and Xpert Ultra
for tuberculosis and rifampicin resistance in adults irrespective
of signs and symptoms of tuberculosis, that is, when used as a
screening test.
Target condition being diagnosed
Tuberculosis is caused by the bacterium Mycobacterium
tuberculosis (M tuberculosis) and is spread from person to person
through the air. Tuberculosis most commonly aJects the lungs
(pulmonary tuberculosis), but may aJect any organ or tissue
outside of the lungs (extrapulmonary tuberculosis). Signs and
symptoms of pulmonary tuberculosis include cough, fever, chills,
night sweats, weight loss, haemoptysis (coughing up blood),
and fatigue. Signs and symptoms of extrapulmonary tuberculosis
depend on the site of disease. Tuberculosis treatment regimens
must contain multiple drugs, to which the organisms are sensitive,
to cure tuberculosis and avoid selection for drug resistance.
The treatment of multidrug-resistant TB (MDR-TB) is complex,
historically requiring two years or more of therapy, although
the WHO conditionally recommended a regimen of nine to 12
months in 2016 (WHO Guidelines 2016). The drugs used to treat
MDR-TB are less potent and more toxic than the drugs used
to treat drug-susceptible tuberculosis. Based on new evidence
on the management of drug-resistant tuberculosis, the WHO
recently released a rapid communication stating that, "All patients
with MDR-TB or rifampicin-resistant tuberculosis, including those
with additional resistance to fluoroquinolones, stand to benefit
from eJective all-oral treatment regimens, either shorter or
longer, implemented under programmatic conditions" (WHO Rapid
Communication 2020b).
Index test(s)
Xpert MTB/RIF is an automated polymerase chain reaction (PCR)
test (molecular test) using the GeneXpert platform (Cepheid
2009). Xpert MTB/RIF is a single test that can detect both M
tuberculosis complex and rifampicin resistance within two hours
aRer starting the test, with minimal hands-on technical time. Unlike
conventional nucleic acid amplification (NAA) tests, Xpert MTB/
RIF is unique because sample processing and PCR amplification
and detection are integrated into a single, self-enclosed test unit,
Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of
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the GeneXpert cartridge. Following sample loading, all steps in the
assay are completely automated and self-contained. In addition,
the assay’s sample reagent, used to liquefy sputum, has potent
tuberculocidal (the ability to kill tuberculosis bacteria) properties
and so largely eliminates biosafety concerns during the test
procedure (Banada 2010). Xpert MTB/RIF requires an uninterrupted
and stable electrical power supply, temperature control, and yearly
calibration of the cartridge modules (Global Laboratory Initiative
2019).
Since Xpert MTB/RIF was released, there have been four
generations of the test (G1, G2, G3, and G4), involving diJerent
soRware and cartridge combinations. G4 contains modifications
that improved determination of rifampicin resistance detection as
previous Xpert MTB/RIF versions had found that some rifampicin
susceptibility results were falsely resistant. In order to improve
on Xpert MTB/RIF sensitivity, Cepheid developed Xpert MTB/RIF
Ultra (hereaRer referred to as Xpert Ultra), a re-engineered assay
that uses a newly developed cartridge but may be run on the
same device aRer a soRware upgrade. Xpert Ultra incorporates
two diJerent multi-copy amplification targets and a larger DNA
reaction chamber than Xpert MTB/RIF (WHO Xpert Ultra 2017). A
laboratory study reported that the limit of detection using Xpert
Ultra improved to 15.6 CFU/mL of sputum compared to 112.6 CFU/
mL for Xpert MTB/RIF (Chakravorty 2017). Of note, Xpert Ultra
has added a new result category, ‘trace call', that corresponds
to the lowest bacillary burden for M tuberculosis detection (WHO
Xpert Ultra 2017). Although no result for rifampicin resistance will
be available for people with trace results, a trace-positive result
is suJicient to initiate anti-tuberculosis therapy in children or
HIV-positive people, according to the WHO report. Xpert Ultra is
available for clinical use and several countries have moved from
using Xpert MTB/RIF to using Xpert Ultra instead. In this Cochrane
Review, we will include studies that used any generation of the
index tests.
Clinical pathway
There are two complementary approaches to detection of active
tuberculosis, Figure 1. The first is the patient-initiated pathway, also
known as passive case finding. The second is the provider-initiated
screening pathway, which represents the analytic framework for
this review (WHO Systematic screening 2015). The index test, either
Xpert MTB/RIF or Xpert Ultra, would be performed as the only
test for pulmonary tuberculosis and rifampicin resistance in adults,
irrespective of signs or symptoms of pulmonary tuberculosis, in
high-risk groups and in primary health facilities or community
settings.
 
Figure 1.   There are two complementary approaches to detection of active tuberculosis. The first is the patient-
initiated pathway, also known as passive case finding. The second is the provider-initiated screening pathway (WHO
Systematic screening 2015), which represents the analytic framework for this review. In the latter pathway, the
index test would be applied as the only test, to adults, irrespective of signs and symptoms of tuberculosis, in high-
risk groups and in primary health facilities or community settings.
 
The purpose of the index tests is screening.
The role of the index tests is replacement for usual practice. This
may include replacement for the WHO four-question symptom
screen.
The downstream consequences of screening include the following.
• True-positive (TP): patients would benefit from rapid diagnosis
and initiation of appropriate treatment.
• True-negative (TN): patients would be spared unnecessary
treatment and would benefit from reassurance, pursuit of an
alternative diagnosis if they have symptoms, and determination
of eligibility for tuberculosis preventive therapy if indicated.
• False-positive (FP): patients would probably experience anxiety
and morbidity caused by additional testing, unnecessary
treatment, and possible adverse events; possible stigma
associated with a tuberculosis or MDR-TB diagnosis; and the
chance that a false-positive result may halt further diagnostic
evaluation of the true underlying condition.
• False-negative (FN): patients would experience an increased
risk of morbidity and mortality, and delayed or inappropriate
Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of
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treatment initiation; there would be risk of ongoing tuberculosis
transmission.
Alternative test(s)
Alternative screening tests for tuberculosis include no screening (or
passive case-finding), and one or more of symptom screening (such
as the WHO four-question symptom screen) and chest X-ray, which
must be further confirmed with a diagnostic test. Other tools that
may be useful in screening include urine lipoarabinomannan (LAM)
testing and smear microscopy, which require additional definitive
drug resistance testing even if used as simultaneous screening
and diagnostic tests. We have previously described selected
alternative tests for detection of pulmonary tuberculosis and
rifampicin resistance (Horne 2019; Lewinsohn 2017; Unitaid 2017).
Recently, we published a Special Collection, curated by Cochrane
contributors, that includes Cochrane Reviews from Cochrane
Infectious Diseases and other systematic reviews from other
international teams. The Special Collection describes key WHO
guidelines on tuberculosis diagnostics, and their underpinning
systematic reviews (Cochrane Special Collection 2019). Below we
review screening tools and highlight several recent developments
in tuberculosis diagnostics.
Numerous symptoms, singly and in combination, have been
proposed to screen for tuberculosis in diJerent settings. A
healthcare or community worker asks the person being screened
if they are experiencing any of the selected symptoms, and those
who report symptoms according to local criteria go on to receive
additional testing such as chest X-ray or diagnostic testing. The
most commonly assessed symptoms are cough (varying duration),
fever, weight loss, drenching night sweats, loss of appetite,
haemoptysis, and fatigue. Single symptoms have modest to low
sensitivity; defining a positive screen as any one or more of
multiple symptoms improves sensitivity but reduces specificity,
consequently increasing the number of diagnostic confirmatory
tests. Accuracy of symptom screening varies with the HIV status of
the people screened. One study found that any one of cough of
any duration, fever of any duration, or night sweats lasting three
or more weeks was the most sensitive combination of symptoms
for identification of tuberculosis in people living with HIV (93%
sensitivity, 36% specificity; Cain 2010). In mixed HIV-positive and
HIV-negative populations, a single symptom of cough of greater
than two weeks' duration identified 35% (95% confidence interval
(CI) 24 to 46) of adults with culture-positive pulmonary tuberculosis
in one systematic review and modelling analysis; any one of a list of
tuberculosis symptoms had 70% sensitivity and 61% specificity for
pulmonary tuberculosis in low-HIV-prevalence settings (van't Hoog
2013).
Chest X-ray can involve posterior-anterior, anterior-posterior, or
lateral recording, or a combination of two or all of these. Major
types of chest X-ray include conventional chest X-ray (producing 36
cm x 43 cm film), digital radiography, and computed radiography.
Chest X-ray findings including hilar lymphadenopathy, cavitary
lesions, and evidence of granulomas can all suggest pulmonary
tuberculosis, but are also nonspecific and must be confirmed
with additional testing. Accurate interpretation of pulmonary
tuberculosis findings on chest X-ray are dependent on the ability
of the individual interpreting the chest X-ray, and wide inter-
observer variation has been reported (Zellweger 2006). Computer-
aided interpretation of chest X-ray for pulmonary tuberculosis is a
promising new technology, especially for resource-limited settings
where expertise in chest X-ray interpretation is limited (Harris 2019).
Smear microscopy is the examination of smears for acid-
fast bacilli (tuberculosis bacteria) under a microscope. The
examination may be performed by light microscopy (Ziehl-
Neelsen), fluorescence microscopy, or light-emitting diode (LED)
fluorescence microscopy. Microscopy cannot distinguish between
drug-susceptible tuberculosis and drug-resistant tuberculosis. The
WHO recommends that microscopy, as the initial diagnostic test,
should be replaced with WHO-recommended rapid tests that
can simultaneously detect tuberculosis and tuberculosis drug
resistance (WHO Compendium of WHO guidelines 2018).
Nucleic acid amplification (NAA) tests are molecular systems that
can detect small quantities of genetic material (DNA or RNA) from
micro-organisms, such as M tuberculosis. The key advantage of NAA
tests is that they are rapid diagnostic tests, potentially providing
results in a few hours. Several new commercial NAA tests are
in the diagnostic pipeline or have recently come to market (e.g.
Truenat MTB, Truenat MTBplus, and Truenat MTB-RIF Dx, Molbio
Diagnostics, India). Truenat MTB, MTB Plus and MTB-RIF Dx assays
show comparable accuracy with Xpert MTB/RIF and Xpert Ultra for
detection of tuberculosis (Truenat MTB and Truenat MTB Plus),
and for sequential detection of rifampicin resistance (Truenat MTB-
Rif Dx). The WHO recommends these tests as initial tests for the
diagnosis of tuberculosis and rifampicin resistance (WHO Rapid
Communication 2020).
Alere Determine TB LAM Ag (AlereLAM, Alere Inc, Waltham, USA) is a
commercially available, point-of-care test for tuberculosis disease
(pulmonary and extrapulmonary tuberculosis). The test detects
lipoarabinomannan (LAM), a component of the bacterial cell wall,
which is present in the urine of some people with tuberculosis.
AlereLAM is performed by placing urine on one end of a test strip,
with results appearing as a band on the strip if tuberculosis is
present. The test is simple, requires no special equipment, and
shows results in 25 minutes (Bjerrum 2019). In two randomized
trials, the use of Alere LAM in HIV-positive inpatients has been
shown to reduce mortality (Gupta-Wright 2018; Peter 2016). Based
on evidence from the randomized trials and a Cochrane Review
(Bjerrum 2019), the WHO recommends that AlereLAM should be
used to assist in the diagnosis of active tuberculosis in HIV-positive
adults, adolescents and children. The full recommendations, which
diJer for inpatients and outpatients, are described here: WHO
Lateral flow LAM 2019.
Fujifilm SILVAMP TB LAM (FuijiLAM, co-developed by Foundation
for Innovative New Diagnostics (FIND), Geneva, Switzerland and
Fujifilm, Tokyo, Japan) is a new, urine-based, point-of-care test for
tuberculosis diagnosis in people living with HIV. In an individual
participant data meta-analysis that included five cohorts of people
living with HIV, FujiLAM was found to have superior sensitivity,
70.7% (95% CI 59.0% to 80.8%), compared to AlereLAM sensitivity
of 42.3% (31.7% to 51.8%), against a microbiological reference
standard; FujiLAM had lower specificity, 90.9% (87.2% to 93.7%),
compared to AlereLAM specificity of 95.3% (92.2% to 97.7%) (Broger
2020).
Alternative molecular methods for drug susceptibility testing
include the commercial line probe assays, GenoType MTBDRplus
assay (MTBDRplus, Hain LifeScience, Nehren, Germany), and the
Nipro NTM+MDRTB detection kit 2 (Nipro, Tokyo, Japan), which
Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of
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detect the presence of mutations associated with drug resistance
to isoniazid and rifampicin (WHO LPA 2016). Advantages of line
probe assays are that they can provide a result for detection of
tuberculosis and drug resistance in one to two days. Drawbacks
are that line probe assays are expensive and need to be used in
intermediate and central laboratories (Unitaid 2017).
Rationale
Xpert MTB/RIF and Xpert Ultra provide obvious benefits for patients
(earlier diagnosis and the opportunity to begin earlier, appropriate
treatment), and for public health (opportunities to interrupt
tuberculosis transmission), especially in countries with a high
tuberculosis burden.
Since 2010, the WHO has recommended the use of Xpert MTB/
RIF as the preferred initial diagnostic test for people thought
to have MDR-TB or HIV-associated tuberculosis (WHO 2011). In
2013, the WHO expanded the recommendations, stating that Xpert
MTB/RIF may be used rather than conventional microscopy and
culture as the initial diagnostic test in all adults suspected of
having tuberculosis (conditional recommendation acknowledging
resource implications, high-quality evidence; WHO Xpert MTB/RIF
2013). In addition, the WHO recommended that following an Xpert
MTB/RIF test that demonstrates rifampicin resistance, subsequent
drug susceptibility testing (e.g. using a line probe assay for second-
line drugs) remains essential to detect resistance to drugs other
than rifampicin (WHO Xpert MTB/RIF 2013). In 2017, based on a
non-inferiority analysis of Xpert Ultra compared with Xpert MTB/RIF
(Dorman 2018), the WHO stated that recommendations on the use
of Xpert MTB/RIF also apply to the use of Xpert Ultra as the initial
diagnostic test for all adults and children with signs and symptoms
of tuberculosis (WHO Xpert Ultra 2017).
We are interested in whether a single test, Xpert MTB/RIF or Xpert
Ultra, can be useful to identify people with active pulmonary
tuberculosis in high-risk populations in community settings or
attending healthcare settings for reasons unrelated to tuberculosis.
This is a diJerent approach than diagnosing active tuberculosis
in people with signs and symptoms of tuberculosis who seek
care in health facilities. We performed this Cochrane Review to
inform an updated WHO policy review on tuberculosis screening,
2020 Revision of the Guidelines for Systematic Screening for
Active Tuberculosis: Updated and Consolidated Recommendations
and Implementation Guidance. The 2020 WHO guidelines will
also include Cochrane and non-Cochrane systematic reviews
on symptom screening, chest radiography, and other tests and
strategies for screening for tuberculosis in adults and children.
O B J E C T I V E S
To determine the accuracy of Xpert MTB/RIF and Xpert Ultra
for screening for tuberculosis in adults irrespective of signs or
symptoms of pulmonary tuberculosis in the general population (i.e.
low-risk population).
To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for
screening of pulmonary tuberculosis in adults in the following high-
risk groups.
• People living with HIV.
• Household contacts of people with tuberculosis.




• People with diabetes mellitus.
• People who abuse alcohol.
• Smokers.
• People residing in prisons.
• Healthcare workers.
To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for the
detection of rifampicin resistance in the general population and in
the high-risk groups and settings described above.
Secondary objectives
To compare the accuracy of Xpert MTB/RIF and Xpert Ultra in the
above high-risk groups and settings.
To investigate potential sources of heterogeneity in accuracy
estimates, including the percentage of participants with
tuberculosis symptoms, tuberculosis burden, tuberculosis/HIV
burden, and MDR-TB burden.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include cross-sectional studies and cohort studies that
assessed the accuracy of one or both index tests for both pulmonary
tuberculosis and rifampicin resistance or pulmonary tuberculosis
alone. We will use abstracts to identify published studies and
include the full publications when they meet our inclusion criteria.
We will only include studies that reported data comparing the index
test(s) to an acceptable reference standard from which we could
extract true positive (TP), true negative (TN), false positive (FP), and
false negative (FN) values. The index tests could be assessed alone
or together with other tests. We will include studies designed to find
people with active tuberculosis in community settings.
We will exclude case reports and studies with a case-control
design, the latter because these types of studies are prone to
bias, in particular, studies enrolling participants with severe disease
and healthy participants without disease. We will exclude drug
resistance surveys.
Participants
Adults, defined as 15 years of age and older, irrespective of
signs or symptoms of pulmonary tuberculosis in the general
population, and adults in high-risk populations, including the
following populations.
• People living with HIV.
• Household contacts of people with tuberculosis.
• Patients attending primary health facilities.
• Homeless people.
• Miners.
• People with diabetes mellitus.
• People who abuse alcohol.
Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of
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• Smokers.
• People residing in prisons.
• Healthcare workers.
The settings of interest are primary healthcare facilities and other
community settings.
We will exclude studies that selected participants for enrolment
based on the results of prior tuberculosis testing, such as symptom
screening or chest radiography.
Index tests
Sputum Xpert MTB/RIF and sputum Xpert Ultra
Index test results are automatically generated (i.e. there is a single
threshold), and the user is provided with a printable test result as
follows.
• MTB (M tuberculosis) DETECTED.
• Rif (rifampicin) resistance DETECTED.
• MTB DETECTED; Rif resistance NOT DETECTED.
• MTB DETECTED; Rif resistance INDETERMINATE.
• MTB NOT DETECTED.
• INVALID (the presence or absence of MTB cannot be
determined).
• ERROR (the presence or absence of MTB cannot be determined).
• NO RESULT (the presence or absence of MTB cannot be
determined)
Xpert Ultra incorporates a semi-quantitative classification for
results: trace, very low, low, moderate, and high. ‘Trace'
corresponds to the lowest bacterial burden for detection of M
tuberculosis (Chakravorty 2017). We will consider a trace result to
mean MTB detected.
Target conditions
The target conditions are active pulmonary tuberculosis and
rifampicin resistance.
Reference standards
For tuberculosis, the reference standards are solid culture or
automated liquid culture.
For rifampicin resistance, the reference standards are culture-
based drug susceptibility testing (DST) and line probe assays (WHO
LPA 2016). Acceptable methods for DST are the proportion method,
performed on solid media, such as Lowenstein-Jensen, and use of
a commercial liquid culture system, such as Mycobacteria Growth
Indicator Tube (MGIT) 960 automated mycobacterial detection
system (BD, USA).
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of
language or publication status (published, unpublished, in press,
and ongoing).
Electronic searches
We will search the following databases without language
restriction, using the search terms and strategy described in
Appendix 1:
• Cochrane Infectious Diseases Specialized Register.
• MEDLINE (OVID, from 1966).
• Embase (OVID, from 1974).
• Science Citation Index - Expanded (from 1900), Conference
Proceedings Citation Index - Science (CPCI-S, from 1990), and
BIOSIS Previews (from 1926); all three from the Web of Science.
• Scopus (Elsevier, from 1970).
• Latin American Caribbean Health Sciences Literature (LILACS)
(BIREME, from 1982).
We will also search ClinicalTrials.gov, the WHO International
Clinical Trials Registry Platform (ICTRP; www.who.int/trialsearch),
and the International Standard Randomized Controlled Trials
Number (ISRCTN) registry (www.isrctn.com/), for trials in progress,
and ProQuest Dissertations & Theses A&I (from 1990) for
dissertations.
Searching other resources
We will review reference lists of included articles and any relevant
review articles identified through the above methods. We will
also contact researchers at the Foundation for Innovative New
Diagnostics (FIND), the WHO Global Tuberculosis Programme, and
other experts in the field of tuberculosis diagnostics for information
on ongoing and unpublished studies.
Data collection and analysis
Selection of studies
We will use Covidence to manage the selection of studies
(Covidence). Two review authors will independently and in parallel
scrutinize titles and abstracts identified from literature searching
to identify potentially eligible studies. We will retrieve the article
of any citation, identified by any review author, for full-text
review. Then, two review authors will independently and in parallel
assess articles for inclusion using the predefined selection criteria.
We will resolve any discrepancies by discussion or with a third
review author. We will record all studies excluded aRer full-text
assessment, along with our reasons for their exclusion in the
Characteristics of excluded studies table and illustrate the study
selection process in a PRISMA diagram (Moher 2009).
Data extraction and management
We will extract data on the following characteristics.
• Author, publication year, study design, country where study was
located, clinical setting.
• Population characteristics: age, gender, smear status, HIV status.
• Index test(s), Xpert MTB/RIF or Xpert Ultra.
• Reference standard.
• Quality Assessment of Studies of Diagnostic Accuracy - Revised
(QUADAS-2) items (Whiting 2011).
• Number of TP, FP, FN, and TN (i.e. true positives, false positives,
false negatives, and true negatives, with respect to culture).
• Number of uninterpretable results for detection of pulmonary
tuberculosis.
• Number of indeterminate results for detection of rifampicin
resistance.
We will classify country income status as either low- and middle-
income or high-income, according to the World Bank List of
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Economies (World Bank 2019). In addition, we will classify ‘country'
as being high burden or not high burden for tuberculosis, TB/HIV,
or MDR-TB, according to the classification by the WHO (WHO Global
TB Report 2019).
Assessment of methodological quality
We will use the QUADAS-2 tool, tailored to this review, to assess
the quality of the included studies (Whiting 2011; Appendix 2).
QUADAS-2 consists of four domains: patient selection, index test,
reference standard, and flow and timing. We will assess all domains
for risk of bias and the first three domains for concerns regarding
applicability. We will present the results of this quality assessment
in text, tables, and graphs.
Statistical analysis and data synthesis
We will perform descriptive analyses for the results of the included
studies using Stata 15 (Stata). We will determine sensitivity
and specificity estimates and 95% confidence intervals (CIs) for
individual studies and generate forest plots using Review Manager
5 (Review Manager 2020).
When possible, we will carry out meta-analyses to estimate the
pooled sensitivity and specificity of the index tests separately for
tuberculosis detection and rifampicin resistance detection. We will
determine pooled accuracy estimates using an adaptation of the
bivariate random-eJects model of Reitsma 2005, which uses the
exact binomial likelihood for the observed proportions (Chu 2006).
The bivariate random-eJects approach will allow us to calculate the
pooled estimates of sensitivity and specificity while accounting for
1. variation in sensitivity and specificity estimates within
individual studies;
2. correlation between sensitivity and specificity across studies;
and
3. variation in sensitivity and specificity between studies.
For analysis of Xpert MTB/RIF or Xpert Ultra accuracy for detection
of rifampicin resistance, we will include participants who
1. were culture-positive;
2. had a valid phenotypic drug susceptibility test (DST) or line
probe assay (LPA) result;
3. were Xpert MTB/RIF or Xpert Ultra tuberculosis-positive; and
4. had a valid Xpert MTB/RIF or Xpert Ultra result for rifampicin
resistance, detected or not detected (susceptible).
Sensitivity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance
detected/phenotypic DST or LPA rifampicin-resistant
Specificity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance not
detected/phenotypic DST or LPA rifampicin-susceptible
We will estimate all models using a Bayesian approach, with low-
information prior distributions, using OpenBUGS soRware (Version
3.2.3; Lunn 2009), along with R (Version 3.3.2; R Core Team 2019).
Under the Bayesian approach, all unknown parameters must be
provided a prior distribution that defines the range of possible
values of the parameter and the likelihood of each of those values
based on information external to the data. In order to let the
observed data determine the final results, we will choose to use
low-information prior distributions over the pooled sensitivity and
specificity parameters and their between-study standard deviation
parameters.
It is known that meta-analysis models can be sensitive to the choice
of prior distributions over between-study standard deviation
parameters. We will therefore carry out sensitivity analyses and
consider alternative prior distributions that are less informative,
allowing a wider range of possible values. To study the sensitivity
of all results to the choice of prior distributions, we will consider
alternative prior distributions that are less informative, allowing a
wider range of possible values. We will include information from
the prior distribution in combination with the observed data in
accordance with Bayes' theorem to obtain a posterior distribution
for each unknown parameter.
Using a sample from the posterior distribution, we can obtain
various descriptive statistics of interest. We will estimate the
median pooled sensitivity and specificity and their 95% credible
intervals (CrIs). The median or the 50% quantile is the value
below which lies 50% of the posterior sample. We will report the
median because the posterior distributions of some parameters
may be skewed and the median would be considered a better point
estimate of the unknown parameter than the mean in such cases.
The 95% CrI is the Bayesian equivalent of the classical (frequentist)
95% CI. (We will indicate 95% CI for individual study estimates
and 95% CrI for pooled study estimates, as appropriate.) The 95%
CrI may be interpreted as an interval that has a 95% probability
of capturing the true value of the unknown parameter, given the
observed data and the prior information.
We will also estimate the ‘predicted' sensitivity and specificity in a
future study together with their 95% CrIs. The predicted estimate
is our best guess for the estimate in a future study and is the same
as the pooled estimate. The CrIs, however, may be diJerent. These
values are derived from the predicted region typically reported in
a bivariate meta-analysis plot. If there is no heterogeneity at all
between studies, the CI (or CrI) around the predicted estimate will
be the same as the CI around the pooled estimate. On the other
hand, if there is considerable heterogeneity between studies, the
CI around the predicted estimate will be much wider than the
CI around the pooled estimate. We will generate bivariate plots
of the credible and prediction regions in the receiver operating
characteristic (ROC) space using R (version 3.3.2; R Core Team 2019).
As we anticipate finding few if any studies that compare the
accuracy of Xpert MTB/RIF and Xpert Ultra in the selected high-
risk groups and settings, we plan to analyse the accuracy estimates
descriptively in text, tables, and forest plots.
Approach to uninterpretable index test results
The index tests report an uninterpretable test result for unexpected
results with any of the internal control measures of the assay.
The uninterpretable rate for detection of pulmonary tuberculosis
is the number of tests classified as ‘invalid', ‘error', or ‘no result'
divided by the total number of index tests performed.
The uninterpretable rate for detection of rifampicin resistance
(referred to as indeterminate rate) is the number of tests classified
as ‘MTB detected; Rif (rifampicin) resistance INDETERMINATE‘
divided by the total number of index test-positive results.
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In previous reviews, we found very few uninterpretable results
reported, and chose to exclude them from the bivariate meta-
analyses (Horne 2019). Instead, we used a Bayesian hierarchical
model for a single proportion to estimate the pooled proportion of
uninterpretable index test results and anticipate that we will do the
same in this review.
Investigations of heterogeneity
We will visually inspect forest plots and the summary receiver
operating characteristic (SROC) plots for heterogeneity. If the
data allow, we will investigate sources of heterogeneity using
bivariate meta-regression analyses. We will consider each source
of heterogeneity to be a single covariate aJecting the pooled
sensitivity or the specificity, or both, in a bivariate meta-analysis
model. We plan to assess the following as categorical study-level
covariates.
Detection of pulmonary tuberculosis
• Percentage of participants with tuberculosis symptoms, 50%
or more with tuberculosis symptoms and less than 50%
tuberculosis symptoms
• High tuberculosis burden, yes or no
• High TB/HIV burden, yes or no
Detection of rifampicin resistance
High MDR-TB burden, yes or no
Sensitivity analyses
If there are suJicient data, we will perform sensitivity analyses to
explore the eJect of risk of bias, population characteristics, and
other factors on the accuracy of Xpert MTB/RIF and Xpert Ultra.
Specifically, we will limit inclusion in the meta-analyses to the
following:
• studies that explicitly represented the use of the index tests for
the screening of individuals irrespective of signs and symptoms
of tuberculosis;
• studies that used liquid culture as the reference standard;
• studies where a consecutive or random sample of participants
were enrolled. We will exclude studies where we answered no or
unclear to the QUADAS-2 patient selection signalling question:
"Could the selection of patients have introduced bias?";
• studies where the reference standard was blinded. We will
exclude studies where we answered no or unclear to the
QUADAS-2 Reference standard signalling question: "Were the
reference standard results interpreted without knowledge of the
results of the index test?";
• studies that accounted for all participants in the analysis. We
will exclude studies where we answered ‘no' or ‘unclear' to
the QUADAS-2 flow and timing signalling question: "Were all
patients included in the analysis?".
Assessment of reporting bias
We will not formally assess reporting bias using funnel plots or
regression tests as these have not been reported as helpful for
diagnostic test accuracy studies (Macaskill 2010).
Summary of findings and assessment of the certainty of the
evidence
We will assess the certainty of the evidence using the GRADE
approach (Balshem 2011; Schünemann 2008; Schünemann 2016),
and GRADEpro GDT 2015 soRware. In the context of a systematic
review, ratings of the certainty of the evidence reflect the extent
of our confidence that the estimates of eJect (including test
accuracy and associations) are correct. As recommended, we will
rate the certainty of the evidence as either high (not downgraded),
moderate (downgraded by one level), low (downgraded by two
levels), or very low (downgraded by more than two levels) for five
domains: risk of bias, indirectness, inconsistency, imprecision, and
publication bias.
For each outcome, we will consider the certainty of the evidence
to begin as high when high-quality observational studies (cross-
sectional or cohort studies) enrolled participants with diagnostic
uncertainty. If we have a reason for downgrading, we will use
our judgement to classify the reason as serious (downgraded by
one level) or very serious (downgraded by two levels). We will
summarize this information in the ‘Summary of findings' tables.
As recommended, we will apply GRADE in the following ways
(Schünemann 2020a; Schünemann 2020b).
• Risk of bias: we will use QUADAS-2 to assess risk of bias.
• Indirectness: we will assess indirectness in relation to the
population (including disease spectrum), setting, interventions,
and outcomes (accuracy measures). For example, we will note
whether the population was the same in the studies compared
to the question asked. We will also use prevalence as a guide to
whether there was indirectness in the population.
• Inconsistency: GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity
estimates. We will carry out prespecified analyses and
downgrade only when we cannot explain inconsistency in the
accuracy estimates.
• Imprecision: we will consider a precise estimate to be one
that would allow a clinically meaningful decision. We will
consider the width of the CrI and ask ourselves, ‘Would we
make a diJerent decision if the lower or upper boundary of
the CrI represented the truth?’ In addition, we will determine
projected ranges for true positives (TP), false negatives (FN), true
negatives (TN), and false positives (FP) for a given prevalence of
tuberculosis and make judgements on imprecision from these
calculations.
• Publication bias: we will consider the comprehensiveness of the
literature search and outreach to researchers in tuberculosis,
the presence of only studies that produce precise estimates of
high accuracy despite small sample size, and knowledge about
studies that were conducted, but are not published.
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#1 Search Tuberculosis or MDR-TB or XDR-TB or tuberculous Field: Title/Abstract
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#2 Search “Mycobacterium tuberculosis” [Mesh]
#3 Search "Tuberculosis"[Mesh] or ("Tuberculosis, Multidrug-Resistant"[Mesh]) OR "Extensively Drug-
Resistant Tuberculosis"[Mesh]
#4 Search ((#3) OR #2) OR #1
#5 Search Xpert* or GeneXpert or Ultra or cepheid Field: Title/Abstract
#6 Search "near* patient*" or near-patient Field: Title/Abstract
#7 Search (#6) OR #5
#8 Search "active case" Field: Title/Abstract
#9 Search "case finding" Field: Title/Abstract
#10 Search prevalence Field: Title/Abstract
#11 Search Asymptomatic Field: Title/Abstract
#12 Search comorbidity or co-morbidity Field: Title/Abstract
#13 Search screening Field: Title/Abstract
#14 Search Detect* or missed or undetect* or undiagnosed Field: Title/Abstract
#15 Search ((((((#14) OR #13) OR #12) OR #11) OR #10) OR #9) OR #8
#16 Search (#4) AND #7 AND #15
  (Continued)
 
Database: Embase 1947-present, updated daily
Search Strategy:
--------------------------------------------------------------------------------
1 (tuberculosis or TB).mp.
2 Tuberculosis, Multidrug-Resistant/ or Extensively Drug-Resistant Tuberculosis/ or Tuberculosis/ or tuberculosis.mp. or Mycobacterium
tuberculosis/
3 (MDR-TB or XDR-TB).mp.
4 1 or 2 or 3
5 Xpert* MTB RIF.ti. or Xpert* MTB RIF.ab.
6 (Xpert* or GeneXpert or cepheid).mp.
7 (near* patient or near-patient).ti. or (near* patient or near-patient).ab.
8 5 or 6 or 7
9 4 and 8
10 detection.mp.
11 diagnostic error/ or missed.mp.
12 (undetected or undiagnosed).mp.
13 asymptomatic.mp.
14 comorbidity.mp. or comorbidity/
15 prevalence/
16 active case finding.mp. or case finding/
17 10 or 11 or 12 or 13 or 14 or 15 or 16
18 9 and 17
Web of Science
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# 3 #2 AND #1
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 2 TOPIC: (asymptomatic or undetected or undiagnosed) OR TOPIC: ("case finding" or
prevalence or comorbidity)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 1 TOPIC: (tuberculosis OR tb OR mycobacterium) AND TOPIC: (xpert* OR genexpert
OR cepheid)




( TITLE-ABS-KEY ( tuberculosis OR tb OR mycobacterium ) AND TITLE-ABS-KEY ( ( xpert* OR genexpert OR cepheid ) ) AND TITLE-ABS-KEY
( asymptomatic OR undetected OR undiagnosed OR "case finding" OR prevalence OR comorbidity ) )
LILAC
(tuberculosis OR TB OR mycobacterium) (Words) AND (xpert OR Genexpert OR Cepheid) (Words)
Appendix 2. QUADAS-2
In QUADAS-2, we will assess methodological quality separately for each of the objectives, Xpert for pulmonary tuberculosis detection and
Xpert for rifampicin resistance detection.
Domain 1: patient selection
Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: was a consecutive or random sample of patients enrolled? We will answer ‘yes' if the study enrolled a consecutive or
random sample of eligible patients; ‘no' if the study selected patients by convenience; and ‘unclear' if the study did not report the manner
of patient selection or we cannot tell.
Signalling question 2: did the study avoid inappropriate exclusions? We will answer ‘yes' if the study included all individuals in the general
population or the high-risk group considered for tuberculosis screening. We will answer ‘no' if the study primarily or exclusively included
individuals with a history of tuberculosis; individuals who had undergone previous treatment (retreatment patients); or those with signs
and symptoms of tuberculosis. We will answer ‘unclear' if we cannot tell.
Applicability: are there concerns that the included patients and setting do not match the review question?
We are interested in how Xpert MTB/RIF or Xpert Ultra perform in patients who were evaluated as they would be in the settings of
intended use. We will answer ‘low concern' if the study population resembled a population that was selected for tuberculosis screening
in community settings or primary care centres. We will answer ‘high concern' if the study population does not resemble a population that
was selected for tuberculosis screening in a community setting. We will answer ‘unclear concern' if there was insuJicient information to
make a decision.
Xpert MTB/RIF and Xpert Ultra for Xpert MTB/RIF or Xpert Ultra rifampicin resistance
Domain 1: patient selection is the same as for MTB/RIF or Xpert Ultra for pulmonary tuberculosis.
Domain 2: index test
Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: were the index test results interpreted without knowledge of the results of the reference standard? We will answer this
question ‘yes' for all studies because Xpert test results were automatically generated and the user was provided with printable test results.
Thus, there is no room for subjective interpretation of test results.
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Signalling question 2: if a threshold was used, was it prespecified? The threshold was prespecified in all versions of Xpert. We will answer
this question ‘yes' for all studies.
For risk of bias, we judge ‘low concern' for all studies.
Applicability: are there concerns that the index test, its conduct, or its interpretation diJer from the review question? Variations in test
technology, execution, or interpretation may aJect estimates of the diagnostic accuracy of a test. All steps in the Xpert MTB/RIF and Xpert
Ultra assays are completely automated and self-contained following sample loading. We will answer ‘low concern' if the index test was
performed as recommended by the manufacturer, which we anticipate will be true for most studies. We will answer ‘unclear concern' if
the ratio of the Xpert MTB/RIF or Xpert Ultra sample reagent: specimen volume was not 2:1 for a raw specimen or 3:1 for a sediment, as
recommended by the manufacturer.
Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance
Domain 2: index test is the same as for MTB/RIF or Xpert Ultra for pulmonary tuberculosis.
Domain 3: reference standard
Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1: is the reference standard likely to correctly classify the target condition?
We will answer ‘yes' for all studies, since culture as a reference standard was a criterion for inclusion in the review.
Signalling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
We will answer ‘yes' if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was
clear that the reference standard was performed at a separate laboratory and/or performed by diJerent people. We will answer ‘no' if the
study stated that the reference standard result was interpreted with knowledge of the Xpert MTB/RIF or Xpert Ultra test result. We will
answer ‘unclear' if we cannot tell.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question? We will
answer ‘high concern' if included studies did not speciate mycobacteria isolated in culture; ‘low concern' if speciation was performed; and
‘unclear concern' if we cannot tell.
Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: is the reference standard likely to correctly classify the target condition?
We will answer ‘yes' if either culture-based drug susceptibility testing (DST) or line probe assay (such as MTBDRplus) was used. These are
the criteria for inclusion for this objective of the review.
Signalling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
We will answer ‘yes' if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was
clear that the reference standard was performed at a separate laboratory and/or performed by diJerent people. We will answer ‘no' if the
study stated that the reference standard result was interpreted with knowledge of the Xpert MTB/RIF or Xpert Ultra test result. We will
answer ‘unclear' if we cannot tell.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question? We will
judge applicability to be of ‘low concern' for those studies evaluating Xpert MTB/RIF or Xpert Ultra for rifampicin resistance because these
specimens had already been identified as Mycobacterium tuberculosis positive.
Domain 4: flow and timing
Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis detection
Risk of bias: could the patient flow have introduced bias?
Signalling question 1: was there an appropriate interval between the index test and reference standard? In most included studies, we expect
that specimens for Xpert MTB/RIF or Xpert Ultra and culture would be obtained at the same time, when patients were screened. However,
even if there were a delay of several days between index test and reference standard, tuberculosis is a chronic disease and we considered
misclassification of disease status to be unlikely, as long as treatment was not initiated in the interim. We will answer ‘yes' if the index test
Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of
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and reference standard were performed at the same time or if the time interval was less than or equal to seven days, ‘no' if the time interval
is greater than seven days, and ‘unclear' if we cannot tell.
Signalling question 2: did all patients receive the same reference standard? We will answer this question ‘yes' for all studies as an acceptable
reference standard (either solid or liquid culture) was specified as a criterion for inclusion in the review. However, we acknowledge that it is
possible that some specimens could undergo solid culture and others liquid culture. This could potentially result in variations in accuracy,
but we think the variation would be minimal.
Signalling question 3: were all patients included in the analysis? We will determine the answer to this question by comparing the number
of patients enrolled with the number of patients included in the 2 x 2 tables. We will answer ‘yes' if the numbers matched and ‘no' if there
were patients enrolled in the study that were not included in the analysis. We will answer ‘unclear' if we cannot tell.
Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance
Domain 4: flow and timing is the same as for Xpert MTB/RIF or Xpert Ultra for pulmonary tuberculosis.
Judgements for ‘Risk of bias' assessments for a given domain
• If we answered all signalling questions for a domain ‘yes', then we will judge risk of bias as ‘low'.
• If we answered all or most signalling questions for a domain ‘no', then we will judge risk of bias as ‘high'.
• If we answered only one signalling question for a domain ‘no', we will discuss further the risk of bias judgement.
• If we answered all or most signalling questions for a domain ‘unclear', then we will judge risk of bias as ‘unclear'.
• If we answered only one signalling question for a domain ‘unclear', we will discuss further the risk of bias judgement for the domain.
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